(Total Views: 645)
Posted On: 11/16/2021 12:57:36 PM
Post# of 8390
Key Items from BIEL's Q3 Update
1) First Profitable Quarter in BIEL's History - and this was accomplished amidst all of the electronic component shortages and supply chain disruptions that Covid has caused
2) First 9 months Revenue in 2021 saw a 463% increase over 2020
3) Australian Partner LMT Surgical reports strong demand and efficacy for RecoveryRx
4) Bangladesh Distributor Roll Out was delayed by Covid, now scheduled for Q1 2022
5) Korean Partner is scheduled for a Q2 2022 Roll Out
6) BIEL is Working on a New Wound Pain Product and is seeking an OEM Partner
7) BIEL R&D is Collaborating with Binghamton University to Develop PSWT for Depression and Anxiety - these conditions afflict 16 million in the US
Major Lenders St Johns & IBEX will Continue to Forgo Interest until at Least Q2 2022
1) First Profitable Quarter in BIEL's History - and this was accomplished amidst all of the electronic component shortages and supply chain disruptions that Covid has caused
2) First 9 months Revenue in 2021 saw a 463% increase over 2020
3) Australian Partner LMT Surgical reports strong demand and efficacy for RecoveryRx
4) Bangladesh Distributor Roll Out was delayed by Covid, now scheduled for Q1 2022
5) Korean Partner is scheduled for a Q2 2022 Roll Out
6) BIEL is Working on a New Wound Pain Product and is seeking an OEM Partner
7) BIEL R&D is Collaborating with Binghamton University to Develop PSWT for Depression and Anxiety - these conditions afflict 16 million in the US
Major Lenders St Johns & IBEX will Continue to Forgo Interest until at Least Q2 2022 
(3)
(0)
